Knight Therapeutics (TSE:GUD) Sets New 52-Week High – What’s Next?

Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high on Friday. The stock traded as high as C$11.09 and last traded at C$11.04, with a volume of 48,763 shares changing hands. The stock had previously closed at C$10.80.

Knight Therapeutics Trading Up 2.9%

The stock has a market capitalization of C$1.09 billion, a P/E ratio of 74.07, a P/E/G ratio of -1,013.50 and a beta of -0.45. The company has a current ratio of 2.28, a quick ratio of 1.79 and a debt-to-equity ratio of 4.29. The business has a 50-day moving average price of C$10.03 and a two-hundred day moving average price of C$9.19.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings results on Thursday, August 6th. The company reported C($0.03) EPS for the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%. The company had revenue of C$143.97 million during the quarter. On average, analysts expect that Knight Therapeutics Inc. will post 0.10 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.